Does lineage plasticity enable escape from CAR-T cell therapy? Lessons from MLL-r leukemia

The clinical success of engineered, CD19-directed chimeric antigen receptor (CAR) T cells in relapsed, refractory B-cell acute lymphoblastic leukemia (B-ALL) has generated great enthusiasm for the use of CAR T cells in patients with cytogenetics that portend a poor prognosis with conventional cytoto...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Wenjuan, Kohler, M. Eric, Fry, Terry, Ernst, Patricia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8611617/
https://www.ncbi.nlm.nih.gov/pubmed/34298117
http://dx.doi.org/10.1016/j.exphem.2021.07.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8611617/
https://www.ncbi.nlm.nih.gov/pubmed/34298117
http://dx.doi.org/10.1016/j.exphem.2021.07.002

Ejemplares similares